Trial Profile

An Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-7349 in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ILKN 421H (Primary) ; Pembrolizumab (Primary) ; Tislelizumab (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man

01 Dec 2025 New trial record
11 Nov 2025 According to the iLeukon Therapeutics media release,new clinical results from this trial presented during a Late-Breaking Clinical Oral Session at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD.
04 Nov 2025 According to the iLeukon Therapeutics media release, summary of this Phase I study was selected as an oral presentation at the upcoming SITC Annual Meeting, and the results will be presented on November 8, 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com